Home / Conditions / Tumor
Tumor: when insurers say no, reviewers often say yes
In 41 published external-review decisions involving tumor, independent physician reviewers overturned the insurer’s denial 63.4% of the time.
Published decisions
41
2001–2026
Overturned
63.4%
26 denials reversed
Most-fought treatments for tumor
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| Genetic Genomic Test | 5 | 80% |
| PET Scan | 4 | 75% |
| Cancer Rx | 3 | 33.3% |
| Chemotherapy | 3 | 0% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 24 | 75% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 17 | 47.1% |
Typical time to a decision
7 days
Most land between 5 and 19 days
Handled as urgent
61%
Expedited when a delay would cause harm
Recent direction
Rising
53.3% → 72.2% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for proton beam radiation therapy. The utilization of proton beam radiation therapy remains an area of debate. Proton beam has unique properties compared to standard photon or x-ray beam in its ability to deposit radiation dose. Oftentimes, fewer proton beams can be utilized to achieve a dose distribution similar to a photon beam. This potentially results in fewer areas of low scattered radiation dose when using proton beams. Proton beam is also beneficial in cases of re-irradiation when there is radiation exposure to adjacent tissues. Currently, the National Comprehensive Cancer Network (NCCN) guidelines state that proton therapy is utilized and strongly indicated in settings where severe toxicities would result if normal tissue constraints cannot be met by photon beam.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for proton beam radiation therapy (60 Gy in 30 fractions). The utilization of proton beams in treating pineal tumors is an area of active investigation. Proton beam has unique properties compared to standard photon or x-ray beam in its ability to deposit radiation doses. Often, fewer proton beams can be utilized to achieve a dose distribution similar to standard x-ray beams, potentially resulting in less radiation exposure to critical organs. Proton therapy is currently utilized and strongly indicated in settings where severe toxicities would result if normal tissue constraints cannot be met by standard x-ray beams.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for proton beam radiation therapy. Leptomeningeal cancer, also known as carcinomatous meningitis, is a rare and aggressive form of cancer that affects the brain and spinal cord. Standard management of patients with leptomeningeal cancer typically involves a multimodal approach that combines radiation therapy, chemotherapy, and supportive care. Radiation therapy is used to target the affected areas of the central nervous system and prevent the cancer from spreading further. Depending on the location and extent of the cancer, radiation therapy may involve whole-brain radiation, focal radiation, or a combination of both. This treatment can help to relieve symptoms such as headaches, seizures, and neurological deficits and may also improve overall survival.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for palliative treatment of the right lateral orbit with proton beam therapy (30 Gy delivered in 10-15 fractions). When treating patients with orbital metastases, the standard of care therapy is with photons. For most patients, intensity-modulated radiation therapy (IMRT) with photons is a highly effective and well-established treatment option for orbital metastases. IMRT offers precise control over the radiation beams, allowing for targeted and conformal radiation delivery to the tumor while minimizing exposure to adjacent healthy structures, such as the optic nerve and eye. The advantages of IMRT include its accessibility, established safety profile, and the ability to deliver high doses of radiation to achieve tumor control.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for tumor was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.